Related Party Transactions	9 Months Ended
Sep. 30, 2022
Related Party Transactions
Related Party Transactions	17. Related Party Transactions The Company’s CareVention HealthCare segment provides medication fulfillment pharmacy services and certain PACE solutions services to a client whose Chief Executive Officer is a member of the Board. For the three months ended September 30, 2022 and 2021, $1,894 and $1,679, respectively, of revenue related to this client was included in the Company’s consolidated statements of operations. For the nine months ended September 30, 2022 and 2021, $5,541 and $4,834, respectively, of revenue related to this client was included in the Company’s consolidated statements of operations. As of September 30, 2022 and December 31, 2021, $225 and $67, respectively, was included in accounts receivable, net, on the Company’s consolidated balance sheets. During the second quarter of 2022, a holder of the Company’s convertible senior subordinated notes became a significant stockholder. The stockholder held approximately $88,429 of the Company’s convertible senior subordinated notes, net of discount, which is presented on the Company’s consolidated balance sheet as of September 30, 2022. See Note 11 for more information on the Company’s convertible senior subordinated notes. On September 13, 2022, the Company entered into a cooperation agreement (the “Cooperation Agreement”) with a significant stockholder of the Company, pursuant to which, among other matters, the Company agreed to effect certain changes to its management team and the composition of the Board of Directors and implement certain corporate governance changes. In connection with the Cooperation Agreement, the Company agreed to reimburse the stockholder $464 of fees incurred, which are included within the accrued expenses and other liabilities on the Company’s consolidated balance sheet as of September 30, 2022. On September 13, 2022, in connection with the entry into separation agreements with two retired named executive officers, the Company incurred $9,927 of separation costs, which included stock-based compensation related to the accelerated vesting of unvested shares of restricted stock, severance payments and benefits, relevant payroll taxes, and outplacement services. These costs are included within general and administrative expenses on the Company’s consolidated statement of operations, of which $1,616 are included within accrued expenses and other liabilities on the Company’s consolidated balance sheet as of September 30, 2022. On September 13, 2022, the Company entered into consulting services agreements with two retired named executive officers to provide certain consulting and advisory services to the Company, including assisting with the transition of key client relationships and strategic business partners and prospects. The consulting services agreements expire on December 31, 2022. The Company did not incur costs pursuant to these consulting services agreements during the three and nine months ended September 30, 2022.

Related Party Transactions

9 Months Ended

Sep. 30, 2022

17. Related Party Transactions

The Company’s CareVention HealthCare segment provides medication fulfillment pharmacy services and certain PACE solutions services to a client whose Chief Executive Officer is a member of the Board. For the three months ended September 30, 2022 and 2021, $1,894 and $1,679, respectively, of revenue related to this client was included in the Company’s consolidated statements of operations. For the nine months ended September 30, 2022 and 2021, $5,541 and $4,834, respectively, of revenue related to this client was included in the Company’s consolidated statements of operations. As of September 30, 2022 and December 31, 2021, $225 and $67, respectively, was included in accounts receivable, net, on the Company’s consolidated balance sheets.

During the second quarter of 2022, a holder of the Company’s convertible senior subordinated notes became a significant stockholder. The stockholder held approximately $88,429 of the Company’s convertible senior subordinated notes, net of discount, which is presented on the Company’s consolidated balance sheet as of September 30, 2022. See Note 11 for more information on the Company’s convertible senior subordinated notes.

On September 13, 2022, the Company entered into a cooperation agreement (the “Cooperation Agreement”) with a significant stockholder of the Company, pursuant to which, among other matters, the Company agreed to effect certain changes to its management team and the composition of the Board of Directors and implement certain corporate governance changes. In connection with the Cooperation Agreement, the Company agreed to reimburse the stockholder $464 of fees incurred, which are included within the accrued expenses and other liabilities on the Company’s consolidated balance sheet as of September 30, 2022.

On September 13, 2022, in connection with the entry into separation agreements with two retired named executive officers, the Company incurred $9,927 of separation costs, which included stock-based compensation related to the accelerated vesting of unvested shares of restricted stock, severance payments and benefits, relevant payroll taxes, and outplacement services. These costs are included within general and administrative expenses on the Company’s consolidated statement of operations, of which $1,616 are included within accrued expenses and other liabilities on the Company’s consolidated balance sheet as of September 30, 2022.

On September 13, 2022, the Company entered into consulting services agreements with two retired named executive officers to provide certain consulting and advisory services to the Company, including assisting with the transition of key client relationships and strategic business partners and prospects. The consulting services agreements expire on December 31, 2022. The Company did not incur costs pursuant to these consulting services agreements during the three and nine months ended September 30, 2022.